| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Historical Data Period | 2019 - 2023 |
| CAGR | 5.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pregabalin Market Analysis
The Pregabalin Market is expected to register a CAGR of 5% during the forecast period.
The high and growing prevalence of epilepsy and related disorders, such as neuropathic pain and anxiety disorders, are expected to be primary growth factors for the pregabalin market. Pregabalin is used in the management and treatment of these disorders. For instance, according to the February 2022 update of the World Health Organization, epilepsy was diagnosed in about 50 million people worldwide, with 80% of this population residing in low- and middle-income countries. Further, as per the same source, about 5 million cases of epilepsy were diagnosed yearly. As per estimates, up to 70% of people living with epilepsy could avoid seizures with the right diagnosis and care. Thus, with the increasing awareness about the disease, the demand for effective treatment is expected to increase, fueling market growth.
The rising geriatric population with neuropathic pain is expected to fuel growth in the pregabalin market further as pregabalin is used in neuropathic pain treatment. As the geriatric population increases around the world, the burden of neuropathic pain is further expected to increase over the forecast period. For instance, according to the United Nations Department of Economic and Social Affairs 2022, 771 million people were 65 years or over globally in 2022, and the elderly population is projected to reach 994 million by 2030 and 1.6 billion by 2050. As the elderly population is highly prone to complications such as painful diabetic neuropathy and post-herpetic neuralgia, the rising elderly population is anticipated to propel market growth.
The introduction of new products to the market is anticipated to drive further growth in the industry during the forecast period. For example, in May 2022, Lupin Pharmaceuticals received approval from the FDA for its ANDA for pregabalin capsules in a range of dosages (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg). Therefore, the launch of generic pregabalin is anticipated to drive market growth due to cost-effectiveness and increased availability.
Hence, due to the abovementioned factors, the pregabalin market is expected to grow during the forecast period. However, the availability of alternative treatments, adverse effects associated with pregabalin, and stringent regulatory policies are expected to restrain the pregabalin market during the forecast period.
Pregabalin Market Trends
Neuropathic Pain Application Segment is Expected to Occupy Significant Share in the Market During the Forecast Period
Neuropathic pain is a type of pain that is frequently persistent, and it typically results from a chronic, progressive nerve illness. However, it can also be brought on by an injury or an infection. An incident or injury does not frequently bring on the discomfort associated with neuropathic pain. Instead, the body sends pain signals to your brain unprompted. The primary causes of neuropathic pain include neuropathic pain diseases, multiple sclerosis, multiple myeloma, and diabetic neuropathy, along with injury or infection.
Pregabalin is used to reduce neuropathic pain by blocking the pain signals; thus, with the rising burden of neuropathic pain and its risk factors, the demand for pregabalin is expected to grow, propelling growth in the segment over the forecast period. For instance, according to a review study published in February 2022 in Cureus, about 3% to 17% of the general population suffers from neuropathic pain, and neuropathy can contribute to chronic pain and be a component of mixed pain syndromes. Hence, the high burden of patients with neuropathic pain is expected to boost the segment's growth during the forecast period.
Moreover, as per the article published in UpToDate in December 2022, diabetic polyneuropathy was the most common neuropathy across many regions worldwide. Furthermore, approximately 50% of patients with diabetes are expected to eventually develop neuropathy. Therefore, the rising diabetes population, along with the rising diabetic population, is anticipated to drive the segment’s growth.
Therefore, the rising prevalence of diabetes and neuropathic pain is expected to drive the segment’s growth.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to register significant market growth during the forecast period.
The factors driving the growth are attributed to the growing prevalence of epilepsy and related diseases, the rising geriatric population, the strong foothold of key market players, and the availability of pregabalin in the region.
The high prevalence of epilepsy in the United States is anticipated to drive market growth. For instance, according to the National Institute of Neurological Disorders and Stroke data reviewed on April 2023, in the United States, 2.3 million adults and more than 450,000 kids and teenagers suffered from epilepsy, with an estimated 150,000 people receiving an epilepsy diagnosis annually. Such a huge prevalence of epilepsy is anticipated to increase the adoption of pregabalin to reduce abnormal brain activity, driving market growth in the region.
Further, new product approvals in the country and their launches are expected to boost market growth during the forecast period. For instance, in December 2022, the US Food and Drug Administration (USFDA) approved Zydus' Pregabalin Capsules of strength 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The approval of drugs in the United States is anticipated to contribute to market growth in the region.
Therefore, due to factors such as the rising prevalence of neurological disorders and key initiatives adopted by market players, North America is expected to occupy a significant share of the pregabalin market over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Pregabalin Industry Overview
The pregabalin market is moderately competitive with a number of established market players. The factors owing to the competition include approvals of generic drugs, rising partnerships among key market payers, and rising launch of different pregabalin formulations, among others. Some of the players operating in the market include Viatris Inc., Amneal Pharmaceuticals LLC, Zydus Group, Sciegen Pharmaceuticals Inc., Teva Pharmaceuticals, Rising Pharmaceuticals Inc., MSN Laboratories Ltd, and Cipla Limited.
Pregabalin Market Leaders
-
Teva Pharmaceuticals
-
Cipla Limited
-
Medley Pharmaceuticals Limited
-
Viatris Inc.
-
Amneal Pharmaceuticals LLC
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Pregabalin Market News
- June 2023: Food and Drug Administration (FDA) approved SinoT's ANDA application for PREGABALIN EXTENDED-RELEASE TABLETS 82.5 mg, 165 mg, and 330 mg for treating neuropathic pain associated with diabetic peripheral neuropathy (DPN) and post-herpetic neuralgia (PHN).
- April 2023: Pakistani pharmaceutical firm AGP Limited acquired a selected portfolio of products from American firm Viatris Inc. The portfolio includes many anti-depressants, including pregabalin, anti-hypertensive, and ophthalmology products.
Pregabalin Industry Segmentation
As per the scope of the report, pregabalin is an anti-convulsive drug used to treat epilepsy, fibromyalgia, neuropathic pain, and other related disorders. It acts by reducing nervous activity and reduces pain. The pregabalin market is segmented by product, application, and geography. By products, the market is segmented as capsules, oral solutions, and other products. By application, the market is segmented as epilepsy, neuropathic pain, anxiety disorder, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report offers the value (USD) for the above segments.
| By Product | Capsules | ||
| Oral Solutions | |||
| Other Products | |||
| By Application | Epilepsy | ||
| Neuropathic Pain | |||
| Anxiety Disorder | |||
| Other Applications | |||
| By Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Rest of Asia-Pacific | |||
| Rest of the World | |||
Need A Different Region or Segment?
Customize Now
Pregabalin Market Research FAQs
What is the current Pregabalin Market size?
The Pregabalin Market is projected to register a CAGR of 5% during the forecast period (2025-2030)
Who are the key players in Pregabalin Market?
Teva Pharmaceuticals, Cipla Limited, Medley Pharmaceuticals Limited, Viatris Inc. and Amneal Pharmaceuticals LLC are the major companies operating in the Pregabalin Market.
Which is the fastest growing region in Pregabalin Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Pregabalin Market?
In 2025, the North America accounts for the largest market share in Pregabalin Market.
What years does this Pregabalin Market cover?
The report covers the Pregabalin Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pregabalin Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Global Pregabalin Industry Report
Statistics for the 2025 Pregabalin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pregabalin analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
